IGC Pharma, Inc. 8-K

What Happened

• IGC Pharma, Inc. announced in an 8-K (filed Jan 2, 2026) that its board approved a change in the company's fiscal year‑end from March 31 to December 31.
• The fiscal year change will be effective on December 31, 2025, and the company intends to file a Transition Report on Form 10‑K covering the nine‑month transition period from April 1, 2025 through December 31, 2025.

Key Details

• Fiscal year-end: changed from March 31 to December 31.
• Effective date: December 31, 2025.
• Transition reporting: IGC will file a Form 10‑K for the nine‑month transition period (Apr 1, 2025–Dec 31, 2025).
• Report filed as Item 5.03 (Amendments to Articles of Incorporation or Bylaws) on the company’s Form 8‑K.

Why It Matters

• The change alters the company’s reporting calendar, so upcoming annual and quarterly filings (including earnings and revenue disclosures) will cover different period lengths and timing than prior years.
• Investors should expect a Form 10‑K covering the nine‑month transition period and be mindful that year‑over‑year comparisons and quarterly results may not be directly comparable across the transition.
• This is an administrative change to the fiscal period; the filing does not report financial results, management changes, or transactions.